AAPL   330.91 (+2.67%)
MSFT   186.72 (+2.08%)
FB   230.28 (+1.76%)
GOOGL   1,436.07 (+1.54%)
AMZN   2,478.70 (+0.74%)
CGC   16.53 (-0.60%)
BABA   219.46 (+0.65%)
MU   53.73 (+4.90%)
GE   7.86 (+1.55%)
TSLA   883.22 (+2.18%)
T   32.75 (+2.96%)
ACB   13.93 (-2.11%)
GILD   76.68 (-1.11%)
DIS   124.59 (+0.73%)
NFLX   418.26 (+0.95%)
BAC   28.09 (+4.89%)
BA   204.79 (+11.12%)
AAPL   330.91 (+2.67%)
MSFT   186.72 (+2.08%)
FB   230.28 (+1.76%)
GOOGL   1,436.07 (+1.54%)
AMZN   2,478.70 (+0.74%)
CGC   16.53 (-0.60%)
BABA   219.46 (+0.65%)
MU   53.73 (+4.90%)
GE   7.86 (+1.55%)
TSLA   883.22 (+2.18%)
T   32.75 (+2.96%)
ACB   13.93 (-2.11%)
GILD   76.68 (-1.11%)
DIS   124.59 (+0.73%)
NFLX   418.26 (+0.95%)
BAC   28.09 (+4.89%)
BA   204.79 (+11.12%)
AAPL   330.91 (+2.67%)
MSFT   186.72 (+2.08%)
FB   230.28 (+1.76%)
GOOGL   1,436.07 (+1.54%)
AMZN   2,478.70 (+0.74%)
CGC   16.53 (-0.60%)
BABA   219.46 (+0.65%)
MU   53.73 (+4.90%)
GE   7.86 (+1.55%)
TSLA   883.22 (+2.18%)
T   32.75 (+2.96%)
ACB   13.93 (-2.11%)
GILD   76.68 (-1.11%)
DIS   124.59 (+0.73%)
NFLX   418.26 (+0.95%)
BAC   28.09 (+4.89%)
BA   204.79 (+11.12%)
AAPL   330.91 (+2.67%)
MSFT   186.72 (+2.08%)
FB   230.28 (+1.76%)
GOOGL   1,436.07 (+1.54%)
AMZN   2,478.70 (+0.74%)
CGC   16.53 (-0.60%)
BABA   219.46 (+0.65%)
MU   53.73 (+4.90%)
GE   7.86 (+1.55%)
TSLA   883.22 (+2.18%)
T   32.75 (+2.96%)
ACB   13.93 (-2.11%)
GILD   76.68 (-1.11%)
DIS   124.59 (+0.73%)
NFLX   418.26 (+0.95%)
BAC   28.09 (+4.89%)
BA   204.79 (+11.12%)
Log in

NASDAQ:BIOCBiocept Stock Price, Forecast & News

$0.48
-0.06 (-11.12 %)
(As of 06/5/2020 03:54 PM ET)
Add
Compare
Today's Range
$0.45
Now: $0.48
$0.52
50-Day Range
$0.38
MA: $0.42
$0.51
52-Week Range
$0.21
Now: $0.48
$1.20
Volume34.90 million shs
Average Volume17.60 million shs
Market Capitalization$62.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Read More
Biocept logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.53 million
Book Value$0.24 per share

Profitability

Net Income$-25,140,000.00
Net Margins-463.52%

Miscellaneous

Employees95
Market Cap$62.88 million
Next Earnings Date8/10/2020 (Estimated)
OptionableOptionable

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.

Biocept (NASDAQ:BIOC) Frequently Asked Questions

How has Biocept's stock been impacted by COVID-19 (Coronavirus)?

Biocept's stock was trading at $0.3769 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BIOC shares have increased by 27.2% and is now trading at $0.4796. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biocept?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biocept.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Biocept.

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) released its earnings results on Wednesday, March, 25th. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.10. The medical research company earned $1.78 million during the quarter. Biocept had a negative net margin of 463.52% and a negative return on equity of 185.80%. View Biocept's earnings history.

What price target have analysts set for BIOC?

2 brokerages have issued 12-month target prices for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Biocept's stock price to reach $1.00 in the next year. This suggests a possible upside of 108.5% from the stock's current price. View analysts' price targets for Biocept.

Has Biocept been receiving favorable news coverage?

Media stories about BIOC stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biocept earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View the latest news aboutBiocept.

Who are some of Biocept's key competitors?

What other stocks do shareholders of Biocept own?

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
  • Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
  • Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Pavel Tsinberg, Director of Technology Devel.

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.48.

How big of a company is Biocept?

Biocept has a market capitalization of $62.88 million and generates $5.53 million in revenue each year. The medical research company earns $-25,140,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Biocept employs 95 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.